Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

NCT02987257 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT02987257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02987257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Lead sponsor
Vanderbilt University Medical Center
Phase
Phase 3
Overall status
Completed
Start date
March 21, 2023
Completion date
October 31, 2025
Enrollment
2 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

stevens-johnson syndrome, toxic epidermal necrolyses